RxDoctor Payments Data

Delores Macksoud, MD

Neurology · Miami, FLNPI 1962594580

Payments from drug & device makers

$757,133in general payments, 2019–2025

Across 454 payments — averaging $1667.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$742K
  • AbbVie$4K
  • EMD Serono, Inc.$2K
  • Biogen$1K
  • Mallinckrodt Hospital Products Inc.$1K
  • UCB, Inc.$1K
  • plus $6K from 44 others

What the payments were for

  • Speaking & faculty fees$2,53918%
  • Food & beverage$11,25081%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757,133 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$7,839
Medicare patients
54
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate27$134,248
Avonex (4 Pack)Interferon Beta-1a12$99,190
RytaryCarbidopa/Levodopa86$83,913
NamzaricMemantine Hcl/Donepezil Hcl96$65,654
Emgality PenGalcanezumab-Gnlm25$22,908
VimpatLacosamide16$22,855
AptiomEslicarbazepine Acetate15$21,493
Nurtec OdtRimegepant Sulfate12$16,666
Rivastigmine60$13,119
Keppra XrLevetiracetam14$12,509
Rasagiline Mesylate26$9,729
Memantine Hcl382$8,882
Memantine Hcl ErMemantine Hcl63$5,649
Gabapentin291$4,558
Lacosamide18$4,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$233$134,24827 claims
BiogenAvonex (4 Pack)$1,178$99,19012 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$815$84,71397 claims
AbbVieNamzaric$3,542$65,65496 claims
UCB, Inc.Vimpat$1,134$22,85516 claims
Sunovion Pharmaceuticals Inc.Aptiom$120$21,49315 claims
PfizerNurtec Odt$122$16,66612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →